REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.04
−1.64%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 17.91x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 13.41x
- Price / sales
- —
- Price / cash flow
- -5.08x
Enterprise value
- Enterprise value
- $1.3B
- EV / sales
- —
- EV / EBITDA
- -4.58x
- EV / EBIT
- -4.48x
- Market cap
- $1.4B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026